| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Dialysis | 72 | 2021 | 276 | 8.440 |
Why?
|
| Kidney Failure, Chronic | 68 | 2021 | 534 | 6.940 |
Why?
|
| Hemodialysis, Home | 12 | 2020 | 13 | 3.060 |
Why?
|
| Antihypertensive Agents | 18 | 2022 | 363 | 2.940 |
Why?
|
| Hypertension | 29 | 2022 | 979 | 2.920 |
Why?
|
| Blood Pressure | 26 | 2022 | 861 | 2.750 |
Why?
|
| Renal Insufficiency, Chronic | 15 | 2020 | 293 | 2.060 |
Why?
|
| Peritoneal Dialysis | 7 | 2020 | 22 | 1.840 |
Why?
|
| Practice Guidelines as Topic | 15 | 2020 | 395 | 1.810 |
Why?
|
| Kidney Diseases | 11 | 2016 | 243 | 1.730 |
Why?
|
| Nephrology | 6 | 2019 | 33 | 1.600 |
Why?
|
| Humans | 143 | 2022 | 32284 | 1.400 |
Why?
|
| Middle Aged | 93 | 2021 | 11853 | 1.230 |
Why?
|
| Glomerular Filtration Rate | 14 | 2020 | 302 | 1.230 |
Why?
|
| Nutritional Status | 10 | 2013 | 73 | 1.170 |
Why?
|
| Female | 98 | 2021 | 19947 | 1.060 |
Why?
|
| Aged | 73 | 2021 | 10265 | 1.060 |
Why?
|
| Male | 98 | 2021 | 19443 | 1.050 |
Why?
|
| Cardiovascular Diseases | 16 | 2022 | 1158 | 0.950 |
Why?
|
| Hospitalization | 11 | 2021 | 475 | 0.950 |
Why?
|
| Blood Pressure Determination | 7 | 2020 | 106 | 0.870 |
Why?
|
| Kidney | 8 | 2018 | 521 | 0.860 |
Why?
|
| United States | 32 | 2020 | 4072 | 0.820 |
Why?
|
| Treatment Outcome | 29 | 2021 | 3416 | 0.820 |
Why?
|
| Hypertrophy, Left Ventricular | 8 | 2021 | 122 | 0.780 |
Why?
|
| Adult | 52 | 2022 | 9259 | 0.760 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 3 | 2020 | 3 | 0.720 |
Why?
|
| Risk Factors | 30 | 2022 | 3934 | 0.720 |
Why?
|
| Apolipoproteins | 8 | 2016 | 194 | 0.710 |
Why?
|
| Renal Insufficiency | 2 | 2020 | 57 | 0.690 |
Why?
|
| Lipoproteins, HDL | 8 | 2016 | 250 | 0.690 |
Why?
|
| Disease Management | 2 | 2014 | 129 | 0.670 |
Why?
|
| Time Factors | 24 | 2021 | 2205 | 0.630 |
Why?
|
| Patient Education as Topic | 3 | 2020 | 245 | 0.630 |
Why?
|
| Randomized Controlled Trials as Topic | 15 | 2020 | 541 | 0.600 |
Why?
|
| Societies, Medical | 2 | 2020 | 153 | 0.590 |
Why?
|
| Kidney Cortex Necrosis | 1 | 2018 | 2 | 0.580 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2018 | 8 | 0.580 |
Why?
|
| Health Services Accessibility | 2 | 2018 | 242 | 0.570 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2020 | 316 | 0.570 |
Why?
|
| Serum Albumin | 11 | 2013 | 56 | 0.570 |
Why?
|
| Foundations | 2 | 2016 | 8 | 0.550 |
Why?
|
| Urea | 11 | 2013 | 38 | 0.540 |
Why?
|
| Quality of Life | 11 | 2020 | 964 | 0.530 |
Why?
|
| Creatinine | 10 | 2021 | 191 | 0.510 |
Why?
|
| Cause of Death | 8 | 2017 | 236 | 0.500 |
Why?
|
| Proportional Hazards Models | 15 | 2019 | 773 | 0.490 |
Why?
|
| Catheterization, Central Venous | 4 | 2008 | 62 | 0.460 |
Why?
|
| Hemodialysis Solutions | 3 | 2016 | 4 | 0.450 |
Why?
|
| Risk Assessment | 13 | 2020 | 1425 | 0.450 |
Why?
|
| Program Development | 2 | 2020 | 93 | 0.430 |
Why?
|
| Ergocalciferols | 1 | 2014 | 3 | 0.430 |
Why?
|
| Aged, 80 and over | 19 | 2021 | 3902 | 0.430 |
Why?
|
| Energy Intake | 6 | 2013 | 122 | 0.430 |
Why?
|
| Cholecalciferol | 1 | 2014 | 25 | 0.420 |
Why?
|
| Anticoagulants | 2 | 2017 | 122 | 0.420 |
Why?
|
| Kidney Transplantation | 6 | 2020 | 490 | 0.410 |
Why?
|
| African Americans | 12 | 2016 | 1335 | 0.400 |
Why?
|
| Clinical Trials as Topic | 4 | 2020 | 312 | 0.400 |
Why?
|
| Vitamin D | 1 | 2014 | 186 | 0.380 |
Why?
|
| Heart Failure | 5 | 2021 | 728 | 0.380 |
Why?
|
| Follow-Up Studies | 18 | 2021 | 2240 | 0.370 |
Why?
|
| Quality Assurance, Health Care | 3 | 2009 | 72 | 0.370 |
Why?
|
| Severity of Illness Index | 7 | 2020 | 853 | 0.370 |
Why?
|
| Medicare | 5 | 2020 | 219 | 0.360 |
Why?
|
| Body Surface Area | 2 | 2008 | 15 | 0.360 |
Why?
|
| Prospective Studies | 15 | 2019 | 2316 | 0.350 |
Why?
|
| Algorithms | 2 | 2019 | 536 | 0.350 |
Why?
|
| Sleep | 1 | 2011 | 84 | 0.340 |
Why?
|
| Cystatin C | 3 | 2020 | 33 | 0.330 |
Why?
|
| Citrates | 1 | 2010 | 5 | 0.330 |
Why?
|
| Diet | 1 | 2013 | 383 | 0.330 |
Why?
|
| Albuminuria | 4 | 2020 | 172 | 0.330 |
Why?
|
| Systole | 6 | 2020 | 94 | 0.330 |
Why?
|
| Consensus | 3 | 2020 | 87 | 0.330 |
Why?
|
| Heparin | 1 | 2010 | 65 | 0.320 |
Why?
|
| Diabetic Nephropathies | 5 | 2016 | 223 | 0.320 |
Why?
|
| Guideline Adherence | 3 | 2013 | 109 | 0.310 |
Why?
|
| Kidney Tubules | 2 | 2020 | 25 | 0.300 |
Why?
|
| Sodium | 2 | 2021 | 41 | 0.290 |
Why?
|
| Patient Compliance | 3 | 2019 | 205 | 0.290 |
Why?
|
| Anemia | 6 | 2009 | 50 | 0.280 |
Why?
|
| Body Size | 1 | 2008 | 35 | 0.280 |
Why?
|
| Disease Progression | 6 | 2021 | 591 | 0.280 |
Why?
|
| Adolescent | 11 | 2022 | 3519 | 0.280 |
Why?
|
| beta 2-Microglobulin | 3 | 2019 | 6 | 0.280 |
Why?
|
| Survival Analysis | 9 | 2018 | 477 | 0.260 |
Why?
|
| Arteriovenous Shunt, Surgical | 6 | 2013 | 46 | 0.260 |
Why?
|
| Appetite | 5 | 2011 | 23 | 0.260 |
Why?
|
| Catheters, Indwelling | 4 | 2010 | 42 | 0.260 |
Why?
|
| Health Personnel | 4 | 2020 | 112 | 0.250 |
Why?
|
| Cohort Studies | 9 | 2018 | 1840 | 0.240 |
Why?
|
| Health Status Indicators | 1 | 2006 | 69 | 0.240 |
Why?
|
| Living Donors | 2 | 2020 | 61 | 0.240 |
Why?
|
| Patients | 2 | 2020 | 46 | 0.240 |
Why?
|
| Kidney Function Tests | 4 | 2016 | 101 | 0.240 |
Why?
|
| Dietetics | 1 | 2005 | 4 | 0.230 |
Why?
|
| Health Status | 5 | 2012 | 355 | 0.230 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2005 | 16 | 0.230 |
Why?
|
| Age Factors | 7 | 2018 | 1179 | 0.230 |
Why?
|
| Cross-Sectional Studies | 10 | 2020 | 1479 | 0.220 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2019 | 1224 | 0.220 |
Why?
|
| Body Weight | 5 | 2013 | 323 | 0.220 |
Why?
|
| Anthropometry | 3 | 2013 | 89 | 0.210 |
Why?
|
| Ultrafiltration | 2 | 2016 | 10 | 0.200 |
Why?
|
| Hyperphosphatemia | 3 | 2011 | 6 | 0.200 |
Why?
|
| Interleukin-18 | 2 | 2020 | 9 | 0.200 |
Why?
|
| Hematocrit | 2 | 2002 | 20 | 0.190 |
Why?
|
| Drug Prescriptions | 1 | 2003 | 54 | 0.190 |
Why?
|
| Risk | 5 | 2019 | 305 | 0.180 |
Why?
|
| Dialysis | 1 | 2002 | 3 | 0.180 |
Why?
|
| Dietary Proteins | 4 | 2011 | 63 | 0.180 |
Why?
|
| Fee-for-Service Plans | 1 | 2002 | 14 | 0.180 |
Why?
|
| Blood Volume | 1 | 2002 | 9 | 0.180 |
Why?
|
| Sex Factors | 5 | 2018 | 657 | 0.180 |
Why?
|
| Nutrition Surveys | 2 | 2022 | 144 | 0.180 |
Why?
|
| Hispanic Americans | 3 | 2016 | 772 | 0.170 |
Why?
|
| Dietary Supplements | 2 | 2014 | 188 | 0.170 |
Why?
|
| Hemodiafiltration | 2 | 2013 | 2 | 0.160 |
Why?
|
| Physical Fitness | 2 | 2012 | 120 | 0.160 |
Why?
|
| Multivariate Analysis | 8 | 2017 | 651 | 0.160 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2021 | 168 | 0.160 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2018 | 133 | 0.160 |
Why?
|
| Education | 1 | 2020 | 31 | 0.160 |
Why?
|
| Myocardial Infarction | 2 | 2022 | 466 | 0.160 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2019 | 1 | 0.160 |
Why?
|
| Communication Barriers | 1 | 2020 | 18 | 0.160 |
Why?
|
| Diuretics | 1 | 2019 | 28 | 0.150 |
Why?
|
| Chemokine CCL2 | 1 | 2020 | 48 | 0.150 |
Why?
|
| Biopsy | 2 | 2018 | 252 | 0.150 |
Why?
|
| Drug Administration Schedule | 2 | 2017 | 276 | 0.150 |
Why?
|
| Drinking | 1 | 2019 | 10 | 0.150 |
Why?
|
| Home Care Services | 1 | 2020 | 51 | 0.150 |
Why?
|
| Water Supply | 1 | 2019 | 8 | 0.150 |
Why?
|
| International Cooperation | 1 | 2019 | 31 | 0.150 |
Why?
|
| Tissue and Organ Procurement | 1 | 2020 | 88 | 0.150 |
Why?
|
| European Continental Ancestry Group | 6 | 2016 | 1076 | 0.150 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 83 | 0.150 |
Why?
|
| Diabetes Complications | 1 | 2020 | 171 | 0.150 |
Why?
|
| Caregivers | 1 | 2020 | 114 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 2 | 2010 | 191 | 0.150 |
Why?
|
| Nutrition Assessment | 2 | 2011 | 48 | 0.140 |
Why?
|
| Evidence-Based Medicine | 3 | 2018 | 212 | 0.140 |
Why?
|
| Congresses as Topic | 1 | 2018 | 42 | 0.140 |
Why?
|
| Prognosis | 8 | 2020 | 1534 | 0.140 |
Why?
|
| Longitudinal Studies | 5 | 2019 | 757 | 0.140 |
Why?
|
| Incidence | 5 | 2021 | 1241 | 0.140 |
Why?
|
| Hemoglobins | 3 | 2016 | 45 | 0.140 |
Why?
|
| Body Mass Index | 6 | 2013 | 863 | 0.140 |
Why?
|
| Survival Rate | 5 | 2020 | 893 | 0.140 |
Why?
|
| Multiple Sclerosis | 1 | 2018 | 62 | 0.130 |
Why?
|
| Reference Standards | 1 | 2017 | 28 | 0.130 |
Why?
|
| Cardiology | 1 | 2019 | 104 | 0.130 |
Why?
|
| Predictive Value of Tests | 6 | 2020 | 883 | 0.130 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 2 | 2014 | 11 | 0.130 |
Why?
|
| Thyroid Function Tests | 1 | 2017 | 3 | 0.130 |
Why?
|
| Hypothyroidism | 1 | 2017 | 10 | 0.130 |
Why?
|
| Thyroid Gland | 1 | 2017 | 16 | 0.130 |
Why?
|
| Renin-Angiotensin System | 1 | 2018 | 173 | 0.130 |
Why?
|
| Cognition | 3 | 2016 | 547 | 0.130 |
Why?
|
| Ventricular Function, Left | 2 | 2021 | 264 | 0.130 |
Why?
|
| Hemorrhage | 1 | 2017 | 95 | 0.130 |
Why?
|
| Hyperprolactinemia | 1 | 2016 | 2 | 0.130 |
Why?
|
| Critical Care | 1 | 2017 | 108 | 0.120 |
Why?
|
| Dementia | 1 | 2019 | 246 | 0.120 |
Why?
|
| Young Adult | 4 | 2020 | 2649 | 0.120 |
Why?
|
| Prevalence | 4 | 2013 | 955 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 717 | 0.120 |
Why?
|
| Regression Analysis | 5 | 2019 | 273 | 0.120 |
Why?
|
| Chi-Square Distribution | 5 | 2017 | 287 | 0.120 |
Why?
|
| Catheterization | 2 | 2013 | 55 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2010 | 158 | 0.110 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 25 | 0.110 |
Why?
|
| Brain | 2 | 2019 | 965 | 0.110 |
Why?
|
| Comorbidity | 5 | 2017 | 565 | 0.110 |
Why?
|
| Weight Gain | 2 | 2016 | 104 | 0.110 |
Why?
|
| Malnutrition | 2 | 2005 | 21 | 0.110 |
Why?
|
| Heart Diseases | 2 | 2007 | 114 | 0.110 |
Why?
|
| National Health Programs | 1 | 2014 | 6 | 0.110 |
Why?
|
| Stroke | 2 | 2017 | 691 | 0.110 |
Why?
|
| Genetic Variation | 2 | 2014 | 248 | 0.110 |
Why?
|
| Bone Density Conservation Agents | 1 | 2014 | 23 | 0.110 |
Why?
|
| Organ Size | 2 | 2019 | 221 | 0.100 |
Why?
|
| Renal Circulation | 1 | 2014 | 12 | 0.100 |
Why?
|
| Furosemide | 1 | 2014 | 8 | 0.100 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 2 | 2011 | 36 | 0.100 |
Why?
|
| Renal Artery Obstruction | 1 | 2014 | 38 | 0.100 |
Why?
|
| Renal Artery | 1 | 2014 | 47 | 0.100 |
Why?
|
| Autoantigens | 1 | 2013 | 15 | 0.100 |
Why?
|
| Glomerulonephritis | 1 | 2013 | 19 | 0.100 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2013 | 6 | 0.100 |
Why?
|
| Body Composition | 4 | 2011 | 327 | 0.100 |
Why?
|
| Patient Care Planning | 1 | 2014 | 55 | 0.100 |
Why?
|
| Ventricular Function, Right | 1 | 2013 | 17 | 0.100 |
Why?
|
| Erythropoietin | 3 | 2003 | 31 | 0.100 |
Why?
|
| Membranes, Artificial | 2 | 2003 | 8 | 0.100 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2013 | 81 | 0.100 |
Why?
|
| Ventricular Remodeling | 1 | 2013 | 63 | 0.100 |
Why?
|
| JC Virus | 1 | 2013 | 20 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2008 | 757 | 0.100 |
Why?
|
| Tumor Virus Infections | 1 | 2013 | 21 | 0.100 |
Why?
|
| Oxygen | 1 | 2014 | 138 | 0.100 |
Why?
|
| Odds Ratio | 3 | 2007 | 456 | 0.100 |
Why?
|
| Polyomavirus Infections | 1 | 2013 | 20 | 0.100 |
Why?
|
| African Continental Ancestry Group | 2 | 2012 | 338 | 0.100 |
Why?
|
| Atrial Fibrillation | 1 | 2017 | 410 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 146 | 0.090 |
Why?
|
| Socioeconomic Factors | 2 | 2011 | 388 | 0.090 |
Why?
|
| Research Design | 3 | 2019 | 314 | 0.090 |
Why?
|
| Insurance Coverage | 1 | 2013 | 80 | 0.090 |
Why?
|
| Ethnic Groups | 2 | 2013 | 450 | 0.090 |
Why?
|
| Eating | 2 | 2003 | 77 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 2013 | 243 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 183 | 0.090 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 556 | 0.090 |
Why?
|
| North America | 1 | 2011 | 31 | 0.090 |
Why?
|
| Activities of Daily Living | 2 | 2011 | 245 | 0.090 |
Why?
|
| Geography | 2 | 2009 | 30 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2013 | 1050 | 0.090 |
Why?
|
| Equipment Design | 1 | 2011 | 178 | 0.080 |
Why?
|
| Product Recalls and Withdrawals | 1 | 2010 | 1 | 0.080 |
Why?
|
| Retrospective Studies | 7 | 2009 | 3628 | 0.080 |
Why?
|
| Urinalysis | 2 | 2021 | 19 | 0.080 |
Why?
|
| Folic Acid | 1 | 2010 | 11 | 0.080 |
Why?
|
| Drug Costs | 1 | 2010 | 46 | 0.080 |
Why?
|
| Homocysteine | 1 | 2010 | 16 | 0.080 |
Why?
|
| Abdominal Fat | 1 | 2010 | 39 | 0.080 |
Why?
|
| Molecular Motor Proteins | 1 | 2010 | 59 | 0.080 |
Why?
|
| Logistic Models | 3 | 2016 | 743 | 0.080 |
Why?
|
| Graft Rejection | 1 | 2011 | 236 | 0.080 |
Why?
|
| Myosin Heavy Chains | 1 | 2010 | 84 | 0.080 |
Why?
|
| Heart Ventricles | 1 | 2010 | 146 | 0.080 |
Why?
|
| Administration, Oral | 3 | 2017 | 200 | 0.080 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 2 | 2020 | 30 | 0.080 |
Why?
|
| Life Style | 1 | 2011 | 393 | 0.070 |
Why?
|
| Water-Electrolyte Balance | 2 | 2016 | 17 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2013 | 821 | 0.070 |
Why?
|
| Heart Failure, Diastolic | 1 | 2009 | 15 | 0.070 |
Why?
|
| Uremia | 2 | 2007 | 9 | 0.070 |
Why?
|
| Patient Selection | 1 | 2010 | 272 | 0.070 |
Why?
|
| Mexican Americans | 1 | 2009 | 52 | 0.070 |
Why?
|
| Ticlopidine | 1 | 2008 | 12 | 0.070 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2008 | 22 | 0.070 |
Why?
|
| Demography | 2 | 2005 | 101 | 0.070 |
Why?
|
| Adipose Tissue | 1 | 2010 | 320 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2009 | 137 | 0.070 |
Why?
|
| Disability Evaluation | 1 | 2009 | 242 | 0.070 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2008 | 79 | 0.070 |
Why?
|
| Thrombosis | 1 | 2008 | 78 | 0.070 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 116 | 0.070 |
Why?
|
| Models, Biological | 1 | 2010 | 408 | 0.070 |
Why?
|
| Genotype | 3 | 2016 | 702 | 0.070 |
Why?
|
| Appointments and Schedules | 1 | 2007 | 21 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2009 | 413 | 0.070 |
Why?
|
| Energy Metabolism | 1 | 2008 | 153 | 0.060 |
Why?
|
| Random Allocation | 3 | 2003 | 247 | 0.060 |
Why?
|
| Recombinant Proteins | 3 | 2003 | 264 | 0.060 |
Why?
|
| Delivery of Health Care | 1 | 2009 | 167 | 0.060 |
Why?
|
| Linear Models | 3 | 2013 | 425 | 0.060 |
Why?
|
| C-Reactive Protein | 1 | 2007 | 227 | 0.060 |
Why?
|
| Metabolic Clearance Rate | 2 | 2003 | 18 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2021 | 308 | 0.060 |
Why?
|
| Medicaid | 2 | 2003 | 101 | 0.060 |
Why?
|
| Liver | 1 | 2008 | 492 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 2 | 2006 | 116 | 0.060 |
Why?
|
| Dialysis Solutions | 2 | 2016 | 5 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 3 | 2010 | 110 | 0.050 |
Why?
|
| Stroke Volume | 2 | 2021 | 417 | 0.050 |
Why?
|
| Amputation | 1 | 2004 | 44 | 0.050 |
Why?
|
| Diet Records | 1 | 2004 | 31 | 0.050 |
Why?
|
| Health Surveys | 2 | 2002 | 175 | 0.050 |
Why?
|
| Diabetic Foot | 1 | 2004 | 23 | 0.050 |
Why?
|
| Leg | 1 | 2004 | 69 | 0.050 |
Why?
|
| Indians, North American | 1 | 2004 | 75 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2018 | 141 | 0.050 |
Why?
|
| Decision Support Techniques | 1 | 2004 | 130 | 0.050 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2003 | 101 | 0.050 |
Why?
|
| Gene Frequency | 2 | 2013 | 211 | 0.050 |
Why?
|
| Health Maintenance Organizations | 1 | 2002 | 16 | 0.050 |
Why?
|
| Feeding Behavior | 1 | 2003 | 154 | 0.050 |
Why?
|
| Death Certificates | 1 | 2002 | 5 | 0.050 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2002 | 82 | 0.040 |
Why?
|
| Autopsy | 1 | 2002 | 37 | 0.040 |
Why?
|
| Hypertension, Renal | 1 | 2002 | 27 | 0.040 |
Why?
|
| Health Services | 1 | 2002 | 40 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2002 | 106 | 0.040 |
Why?
|
| Nutrition Disorders | 1 | 2001 | 10 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 1 | 2001 | 62 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2004 | 390 | 0.040 |
Why?
|
| Canada | 2 | 2012 | 63 | 0.040 |
Why?
|
| Bolivia | 1 | 2021 | 3 | 0.040 |
Why?
|
| Iron | 1 | 2001 | 94 | 0.040 |
Why?
|
| Nepal | 1 | 2021 | 11 | 0.040 |
Why?
|
| Malawi | 1 | 2021 | 22 | 0.040 |
Why?
|
| Terminology as Topic | 2 | 2013 | 68 | 0.040 |
Why?
|
| Phenotype | 2 | 2013 | 622 | 0.040 |
Why?
|
| Clinical Protocols | 2 | 2014 | 77 | 0.040 |
Why?
|
| International Agencies | 1 | 2020 | 10 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2021 | 135 | 0.040 |
Why?
|
| Developing Countries | 1 | 2021 | 57 | 0.040 |
Why?
|
| Internationality | 1 | 2020 | 22 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2022 | 160 | 0.040 |
Why?
|
| Matrix Metalloproteinases | 1 | 2019 | 8 | 0.040 |
Why?
|
| Dehydration | 1 | 2019 | 8 | 0.040 |
Why?
|
| Alpha-Globulins | 1 | 2019 | 1 | 0.040 |
Why?
|
| Mexico | 1 | 2019 | 47 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2019 | 192 | 0.040 |
Why?
|
| Patient Participation | 1 | 2020 | 90 | 0.040 |
Why?
|
| Community Health Services | 1 | 2019 | 47 | 0.040 |
Why?
|
| Diarrhea | 1 | 2019 | 56 | 0.040 |
Why?
|
| Acute Disease | 1 | 2019 | 253 | 0.040 |
Why?
|
| American Heart Association | 1 | 2019 | 92 | 0.040 |
Why?
|
| Multiple Organ Failure | 1 | 2008 | 10 | 0.040 |
Why?
|
| North Carolina | 2 | 2013 | 1300 | 0.030 |
Why?
|
| Remission Induction | 1 | 2018 | 92 | 0.030 |
Why?
|
| Pyridones | 1 | 2017 | 10 | 0.030 |
Why?
|
| Infant | 1 | 2021 | 1010 | 0.030 |
Why?
|
| Warfarin | 1 | 2017 | 32 | 0.030 |
Why?
|
| Thiazoles | 1 | 2017 | 36 | 0.030 |
Why?
|
| Pyridines | 1 | 2017 | 79 | 0.030 |
Why?
|
| Critical Illness | 1 | 2008 | 87 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2017 | 77 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2021 | 1233 | 0.030 |
Why?
|
| Puerto Rico | 1 | 2016 | 11 | 0.030 |
Why?
|
| Verbal Learning | 1 | 2016 | 7 | 0.030 |
Why?
|
| Phosphorus | 1 | 2016 | 11 | 0.030 |
Why?
|
| Executive Function | 1 | 2016 | 52 | 0.030 |
Why?
|
| Goals | 1 | 2015 | 34 | 0.030 |
Why?
|
| Attention | 1 | 2016 | 84 | 0.030 |
Why?
|
| Reaction Time | 1 | 2016 | 123 | 0.030 |
Why?
|
| Acute Coronary Syndrome | 1 | 2017 | 167 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 2016 | 108 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2016 | 327 | 0.030 |
Why?
|
| Child | 1 | 2021 | 2435 | 0.030 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2014 | 9 | 0.030 |
Why?
|
| Calcium Channel Blockers | 1 | 2014 | 53 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2014 | 59 | 0.030 |
Why?
|
| Memory | 1 | 2016 | 202 | 0.030 |
Why?
|
| Data Collection | 1 | 2014 | 171 | 0.030 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2013 | 13 | 0.030 |
Why?
|
| Epistasis, Genetic | 1 | 2013 | 43 | 0.030 |
Why?
|
| Skinfold Thickness | 1 | 2013 | 7 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 146 | 0.020 |
Why?
|
| Nonlinear Dynamics | 1 | 2013 | 77 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2013 | 55 | 0.020 |
Why?
|
| Blood Urea Nitrogen | 1 | 2013 | 12 | 0.020 |
Why?
|
| Buffers | 1 | 2013 | 12 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2013 | 184 | 0.020 |
Why?
|
| Water | 1 | 2013 | 65 | 0.020 |
Why?
|
| Urodynamics | 1 | 2013 | 88 | 0.020 |
Why?
|
| Heredity | 1 | 2012 | 12 | 0.020 |
Why?
|
| Pedigree | 1 | 2012 | 136 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2013 | 854 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 186 | 0.020 |
Why?
|
| Electric Impedance | 1 | 2011 | 13 | 0.020 |
Why?
|
| Exercise Test | 1 | 2012 | 217 | 0.020 |
Why?
|
| HLA Antigens | 1 | 2011 | 40 | 0.020 |
Why?
|
| Homozygote | 1 | 2010 | 52 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 158 | 0.020 |
Why?
|
| Vitamin B 6 | 1 | 2010 | 2 | 0.020 |
Why?
|
| Vitamin B 12 | 1 | 2010 | 7 | 0.020 |
Why?
|
| Proteinuria | 1 | 2010 | 52 | 0.020 |
Why?
|
| Hyperhomocysteinemia | 1 | 2010 | 5 | 0.020 |
Why?
|
| Family Health | 1 | 2010 | 73 | 0.020 |
Why?
|
| Housing | 1 | 2010 | 35 | 0.020 |
Why?
|
| Fear | 1 | 2010 | 42 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2011 | 186 | 0.020 |
Why?
|
| Graft Survival | 1 | 2011 | 293 | 0.020 |
Why?
|
| Educational Status | 1 | 2010 | 167 | 0.020 |
Why?
|
| Self Care | 1 | 2010 | 97 | 0.020 |
Why?
|
| Perception | 1 | 2010 | 99 | 0.020 |
Why?
|
| Motivation | 1 | 2010 | 120 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2011 | 248 | 0.020 |
Why?
|
| Waiting Lists | 1 | 2009 | 34 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2011 | 484 | 0.020 |
Why?
|
| Hand Strength | 1 | 2009 | 98 | 0.020 |
Why?
|
| Transplants | 1 | 2008 | 22 | 0.020 |
Why?
|
| Vascular Patency | 1 | 2008 | 66 | 0.020 |
Why?
|
| Reference Values | 1 | 2008 | 238 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 1437 | 0.020 |
Why?
|
| Walking | 1 | 2009 | 200 | 0.020 |
Why?
|
| Protein-Energy Malnutrition | 1 | 2007 | 4 | 0.020 |
Why?
|
| Depression | 1 | 2010 | 420 | 0.020 |
Why?
|
| Treatment Refusal | 1 | 2006 | 14 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2008 | 565 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 2006 | 46 | 0.010 |
Why?
|
| Healthcare Disparities | 1 | 2008 | 180 | 0.010 |
Why?
|
| Inflammation | 1 | 2007 | 506 | 0.010 |
Why?
|
| Cholesterol | 1 | 2005 | 262 | 0.010 |
Why?
|
| Myocardial Ischemia | 1 | 2004 | 98 | 0.010 |
Why?
|
| Length of Stay | 1 | 2004 | 321 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2002 | 36 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2002 | 99 | 0.010 |
Why?
|
| Mental Health | 1 | 2002 | 111 | 0.010 |
Why?
|
| Proteins | 1 | 2002 | 149 | 0.010 |
Why?
|